Akcea Therapeutics, Inc. Selling, General and Administrative Expense
Akcea Therapeutics, Inc. reported Selling, General and Administrative Expense of $42.14 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2020-08-05
- Akcea Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2020-06-30 was $42.14M, a 16.95% decline year-over-year.
- Akcea Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2020-03-31 was $46.25M, a 3.69% increase year-over-year.
- Akcea Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2019-12-31 was $51.43M, a 11.97% increase year-over-year.
- Akcea Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2019-09-30 was $34.91M, a 23.99% decline year-over-year.
- Akcea Therapeutics, Inc. selling, general and administrative expense for fiscal 2019 was $181.68M, a 18.27% increase from fiscal 2018.
- Akcea Therapeutics, Inc. selling, general and administrative expense for fiscal 2018 was $153.61M, a 315.38% increase from fiscal 2017.
- Akcea Therapeutics, Inc. selling, general and administrative expense for fiscal 2017 was $36.98M, a 145.67% increase from fiscal 2016.
- Akcea Therapeutics, Inc. selling, general and administrative expense for fiscal 2016 was $15.05M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2020-06-30 | $42.14M 10-Q · filed 2020-08-05 | $88.39M 10-Q · filed 2020-08-05 | $139.82M derived: sum of 3 quarters · filed 2020-08-05 | $174.72M derived: sum of 4 quarters · filed 2020-08-05 |
| 2020-03-31 | $46.25M 10-Q · filed 2020-05-06 | $97.68M derived: sum of 2 quarters · filed 2020-05-06 | $132.59M derived: sum of 3 quarters · filed 2020-05-06 | $183.32M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-12-31 | $51.43M 10-K · filed 2020-03-02 | $86.34M derived: sum of 2 quarters · filed 2020-03-02 | $137.08M derived: sum of 3 quarters · filed 2020-08-05 | $181.68M 10-K · filed 2020-03-02 |
| 2019-09-30 | $34.91M 10-K · filed 2020-03-02 | $85.64M derived: sum of 2 quarters · filed 2020-08-05 | $130.25M 10-Q · filed 2019-11-06 | $176.18M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-06-30 | $50.74M 10-Q · filed 2020-08-05 | $95.34M 10-Q · filed 2020-08-05 | $141.28M derived: sum of 3 quarters · filed 2020-08-05 | $187.20M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $44.60M 10-Q · filed 2020-05-06 | $90.54M derived: sum of 2 quarters · filed 2020-05-06 | $136.46M derived: sum of 3 quarters · filed 2020-05-06 | $178.75M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $45.93M 10-K · filed 2020-03-02 | $91.86M derived: sum of 2 quarters · filed 2020-03-02 | $134.15M derived: sum of 3 quarters · filed 2020-03-02 | $153.61M 10-K · filed 2020-03-02 |
| 2018-09-30 | $45.92M 10-K · filed 2020-03-02 | $88.21M derived: sum of 2 quarters · filed 2020-03-02 | $107.68M 10-Q · filed 2019-11-06 | $124.69M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $42.29M 10-K · filed 2020-03-02 | $61.75M 10-Q · filed 2019-08-07 | $78.77M derived: sum of 3 quarters · filed 2020-03-02 | $87.14M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $19.46M 10-K · filed 2020-03-02 | $36.48M derived: sum of 2 quarters · filed 2020-03-02 | $44.86M derived: sum of 3 quarters · filed 2020-03-02 | $51.77M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $17.02M 10-K · filed 2019-03-01 | $25.39M derived: sum of 2 quarters · filed 2019-03-01 | $32.31M derived: sum of 3 quarters · filed 2019-03-01 | $36.98M 10-K · filed 2020-03-02 |
| 2017-09-30 | $8.37M 10-K · filed 2019-03-01 | $15.29M derived: sum of 2 quarters · filed 2019-03-01 | $19.96M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $6.92M 10-K · filed 2019-03-01 | $11.59M derived: sum of 2 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $4.68M 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $15.05M 10-K · filed 2019-03-01 |